ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: A model for erbB-2 negative human breast cancer

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Santos, Sara ^a   Baptista, Cláudia S ^a,b   Abreu, Rui M V ^a,c   Bastos, Estela ^a   Amorim, Irina ^b   Gut, Ivo G ^d   Gärtner, Fátima ^b   Chaves, Raquel ^a  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSTITUTO POLITÉCNICO DE BRAGANÇA   (Portugal)

^d CENTRE NATIONAL DE GÉNOTYPAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; ERBB2 GENE; EXON; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; HAPLOTYPE; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; TRANSCRIPTION REGULATION;

ANIMALS; BREAST NEOPLASMS; CATS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENES, ERBB-2; GENETIC VARIATION; MOLECULAR SEQUENCE DATA; PROTEINS; RNA;

EID: 84891317175     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083673     Document Type: Article

References (90)

1. Hansen K, Khanna C (2004) Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 40: 858-880. (Pubitemid 38519765)
2. Zappulli V, De Zan G, Cardazzo B, Bargelloni L, Castagnaro M (2005) Feline mammary tumours in comparative oncology. J Dairy Res 72 Spec No: 98-106. (Pubitemid 41323101)
3. Clarke R (2009) The role of preclinical animal models in breast cancer drug development. Breast Cancer Res 11 Suppl 3: S22.
4. Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, et al. (2010) Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 10: 156.
5. Perez-Alenza MD, Jimenez A, Nieto AI, Pena L (2004) First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases. Breast Cancer Res 6: R300-307.
6. Misdorp W (2002) Tumors of the mammary gland. In: Meuten DJ, editor. Tumors in domestic animals. 4 ed.Iowa: Blackwell. pp. 575-606.
7. MacEwen EG (1990) Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 9: 125-136.
8. Weijer K, Hart AA (1983) Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 70: 709-716. (Pubitemid 13079152)
9. Rutteman GR WS, MacEwen EG (2001) Tumors of the mammary gland In Small Animal Clinical Oncology; Withrow SJ MB, editor. Philadelphia: W.B. Saunders Company.
10. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, et al. (1992) Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci U S A 89: 4658-4662.
11. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, et al. (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60: 854-857. (Pubitemid 30129514)
12. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370. (Pubitemid 38579482)
13. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53. (Pubitemid 36331965)
14. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, et al. (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12: 57-61. (Pubitemid 43166176)
15. Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, et al. (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79: 355-364. (Pubitemid 36750943)
16. Benusiglio PR, Lesueur F, Luccarini C, Conroy DM, Shah M, et al. (2005) Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7: R204-209.
17. Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, et al. (2003) The HER2 I655V polymorphism and risk of breast cancer in women, age 40 years. Cancer Epidemiol Biomarkers Prev 12: 1109-1111. (Pubitemid 37310272)
18. Klapper LN, Kirschbaum MH, Sela M, Yarden Y (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79. (Pubitemid 29439302)
19. Hu X, Su F, Qin L, Jia W, Gong C, et al. (2006) Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Biochem Biophys Res Commun 346: 778-785.
20. Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, et al. (2008) Highresolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 47: 530-542. (Pubitemid 351657188)
21. Teschendorff AE, Caldas C (2009) The breast cancer somatic 'muta-ome': tackling the complexity. Breast Cancer Res 11: 301.
22. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
23. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, et al. (2008) Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 105: 16224-16229.
24. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037. (Pubitemid 32267972)
25. Dibb NJ, Dilworth SM, Mol CD (2004) Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4: 718-727. (Pubitemid 39215070)
26. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, et al. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646. (Pubitemid 40478587)
27. Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135: 55-62.
28. Hishida A, Hamajima N, Iwata H, Matsuo K, Hirose K, et al. (2002) Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94: 1807-1808. (Pubitemid 36004357)
29. Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173: 37-41. (Pubitemid 32907507)
30. Benusiglio PR, Pharoah PD, Smith PL, Lesueur F, Conroy D, et al. (2006) HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer 95: 1689-1695. (Pubitemid 44950795)
31. Han W, Kang D, Lee JE, Park IA, Choi JY, et al. (2005) A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res 11: 4775-4778.
32. Breyer JP, Sanders ME, Airey DC, Cai Q, Yaspan BL, et al. (2009) Heritable variation of ERBB2 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 18: 1252-1258.
33. Potemski P, Pluciennik E, Bednarek AK, Kusinska R, Pasz-Walczak G, et al. (2006) A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry. Med Sci Monit 12: MT57- 61. (Pubitemid 44916066)
34. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, et al. (2005) Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11: 3315-3319. (Pubitemid 40627881)
35. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, et al. (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337. (Pubitemid 20225674)
36. Charpin C, Garcia S, Bouvier C, Martini F, Lavaut MN, et al. (1997) c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 75: 1667-1673. (Pubitemid 27229059)
37. Ginestier C, Charafe-Jauffret E, Penault-Llorca F, Geneix J, Adelaide J, et al. (2004) Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 202: 286-298. (Pubitemid 38325237)
38. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, et al. (2005) Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 65: 907-912. (Pubitemid 40216450)
39. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, et al. (2003) Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106: 758-765. (Pubitemid 36993401)
40. Koletsa T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, et al. (2008) A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia 10: 687-696. (Pubitemid 351883885)
41. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A (2005) Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 42: 30-34. (Pubitemid 40187494)
42. Winston J, Craft DM, Scase TJ, Bergman PJ (2005) Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol 3: 8-15.
43. Ordas J, Millan Y, Dios R, Reymundo C, de Las Mulas JM (2007) Protooncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 7: 179.
44. Santos S, Bastos E, Baptista CS, Sa D, Caloustian C, et al. (2012) Sequence Variants and Haplotype Analysis of Cat ERBB2 Gene: A Survey on Spontaneous Cat Mammary Neoplastic and Non-Neoplastic Lesions. Int J Mol Sci 13: 2783-2800.
45. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-1453.
46. Namba R, Maglione JE, Davis RR, Baron CA, Liu S, et al. (2006) Heterogeneity of mammary lesions represent molecular differences. BMC Cancer 6: 275.
47. Campbell LL, Polyak K (2007) Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6: 2332-2338. (Pubitemid 350058682)
48. Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, et al. (2007) Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat 102: 143-155. (Pubitemid 46452166)
49. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, et al. (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14: 320-368.
50. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, et al. (2001) HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14: 1079-1086. (Pubitemid 33063199)
51. Tommasi S, Fedele V, Lacalamita R, Crapolicchio A, Perlino E, et al. (2004) Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett 209: 215-222. (Pubitemid 38670491)
52. Millikan RC, Hummer AJ, Wolff MS, Hishida A, Begg CB (2005) HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat 89: 309-312. (Pubitemid 43293080)
53. Dahabreh IJ, Murray S (2011) Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 35: 503-509.
54. Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358: 2796- 2803. (Pubitemid 351930854)
55. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115.
56. Nelson SE, Gould MN, Hampton JM, Trentham-Dietz A (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7: R357-364.
57. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, et al. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89: 10578-10582.
58. Onay VU, Briollais L, Knight JA, Shi E, Wang Y, et al. (2006) SNP-SNP interactions in breast cancer susceptibility. BMC Cancer 6: 114.
59. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, et al. (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11: 495- 505. (Pubitemid 36293841)
60. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760. (Pubitemid 36227628)
61. Rajasekaran R, George PDC, Sudandiradoss C, Ramanathan K, Purohit R, et al. (2008) Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. C R Biol 331: 409-417.
62. Soares M, Correia J, Rodrigues P, Simöes M, Matos A, et al. (2013) Feline HER2 Protein Expression Levels and Gene Status in Feline Mammary Carcinoma: Optimization of Immunohistochemistry (IHC) and In Situ Hybridization (ISH) Techniques. Microsc Microanal 19: 1-7.
63. Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V (2011) An Immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol 144: 170-179.
64. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, et al. (2000) Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 36: 170- 176. (Pubitemid 30102192)
65. Gullick WJ, Srinivasan R (1998) The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 52: 43-53. (Pubitemid 29056084)
66. Jimenez RE, Wallis T, Tabasczka P, Visscher DW (2000) Determination of Her- 2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13: 37-45. (Pubitemid 30077902)
67. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, et al. (2001) Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 14: 677-685. (Pubitemid 32667212)
68. Selvarajan S, Bay BH, Chng MJ, Tan PH (2004) The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference? Ann Acad Med Singapore 33: 473-476.
69. Gouvêa AP, Fernandes JRM, Olson SJ, Brandäo EC, Leite MT, et al. (2004) HER-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTestTM. Jornal Brasileiro de Patologia e Medicina Laboratorial 40: 27-32.
70. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, et al. (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45: 1148-1156. (Pubitemid 29424251)
71. Kraus MH, Popescu NC, Amsbaugh SC, King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605-610.
72. Tao W, Wang C, Han R, Jiang H (2009) HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 114: 371-376.
73. Cuadros M, Talavera P, Lopez FJ, Garcia-Perez I, Blanco A, et al. (2010) Realtime RT-PCR analysis for evaluating the Her2/neu status in breast cancer. Pathobiology 77: 38-45.
74. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, et al. (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749. (Pubitemid 32691885)
75. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638. (Pubitemid 47073544)
76. Miller SJ, Xing X, Xi L, Hung MC (1996) Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. DNA Cell Biol 15: 749-757. (Pubitemid 26332478)
77. Bremm A, Walch A, Fuchs M, Mages J, Duyster J, et al. (2008) Enhanced activation of epidermal growth factor receptor caused by tumor-derived Ecadherin mutations. Cancer Res 68: 707-714. (Pubitemid 351206746)
78. Carraro DM, Ferreira EN, Molina GC, Puga RD, Abrantes EF, et al. (2011) Poly (A) + Transcriptome Assessment of ERBB2-Induced Alterations in Breast Cell Lines. PLoS ONE 6(6): e21022.
79. Camp RL, Dolled-Filhart M, King BL, Rimm DL (2003) Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 63: 1445- 1448. (Pubitemid 36373626)
80. Cooke T, Reeves J, Lannigan A, Stanton P (2001) The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 37 Suppl 1: S3-10.
81. Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, et al. (2009) Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 33: 759-767. cancer. Am J Surg Pathol 33: 759-767.
82. Baptista CS, Santos S, Laso A, Bastos E, Avila S, et al. (2012) Sequence variation and mRNA expression of the TWIST1 gene in cats with mammary hyperplasia and neoplasia. Vet J 191: 203-207.
83. Misdorp W ER, Helmén E, Lipscomb TP (1999) Histological Classification of Mammary Tumors of the Dog and Cat. Washington, USA: Armed Forces Institute of Pathology and World Health Organization.
84. Matos AJ, Baptista CS, Gartner MF, Rutteman GR (2012) Prognostic studies of canine and feline mammary tumours: the need for standardized procedures. Vet J 193: 24-31.
85. Gimenez F, Hecht S, Craig LE, Legendre AM (2010) Early detection, aggressive therapy: optimizing the management of feline mammary masses. J Feline Med Surg 12: 214-224.
86. Santos S, Sa D, Bastos E, Guedes-Pinto H, Gut I, et al. (2009) An efficient protocol for genomic DNA extraction from formalin-fixed paraffin-embedded tissues. Res Vet Sci 86: 421-426.
87. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120. (Pubitemid 38085242)
88. Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201. (Pubitemid 43205406)
89. Bagossi P, Horvath G, Vereb G, Szollosi J, Tozser J (2005) Molecular modelling of nearly full-length ErbB2 receptor. Biophys J 88: 1354-1363. (Pubitemid 40975962)
90. Schrödinger L (2011) Maestro. 9.2 ed. New York, NY.